Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.08
TEVJF's Cash to Debt is ranked lower than
57% of the 771 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.69 vs. TEVJF: 0.08 )
TEVJF' s 10-Year Cash to Debt Range
Min: 0.07   Max: No Debt
Current: 0.08

Equity to Asset 0.49
TEVJF's Equity to Asset is ranked higher than
57% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.61 vs. TEVJF: 0.49 )
TEVJF' s 10-Year Equity to Asset Range
Min: 0.39   Max: 0.6
Current: 0.49

0.39
0.6
Interest Coverage 5.25
TEVJF's Interest Coverage is ranked higher than
50% of the 431 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 124.75 vs. TEVJF: 5.25 )
TEVJF' s 10-Year Interest Coverage Range
Min: 3.6   Max: 328.25
Current: 5.25

3.6
328.25
F-Score: 7
Z-Score: 1.74
M-Score: -2.66
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 8.12
TEVJF's Operating margin (%) is ranked higher than
72% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.93 vs. TEVJF: 8.12 )
TEVJF' s 10-Year Operating margin (%) Range
Min: 8.12   Max: 26.78
Current: 8.12

8.12
26.78
Net-margin (%) 6.25
TEVJF's Net-margin (%) is ranked higher than
71% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.07 vs. TEVJF: 6.25 )
TEVJF' s 10-Year Net-margin (%) Range
Min: 5.73   Max: 21.09
Current: 6.25

5.73
21.09
ROE (%) 5.62
TEVJF's ROE (%) is ranked higher than
68% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. TEVJF: 5.62 )
TEVJF' s 10-Year ROE (%) Range
Min: 3.9   Max: 22.43
Current: 5.62

3.9
22.43
ROA (%) 2.67
TEVJF's ROA (%) is ranked higher than
68% of the 746 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.87 vs. TEVJF: 2.67 )
TEVJF' s 10-Year ROA (%) Range
Min: 1.93   Max: 11.68
Current: 2.67

1.93
11.68
ROC (Joel Greenblatt) (%) 18.01
TEVJF's ROC (Joel Greenblatt) (%) is ranked higher than
77% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.90 vs. TEVJF: 18.01 )
TEVJF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 12.03   Max: 47.4
Current: 18.01

12.03
47.4
Revenue Growth (%) 10.90
TEVJF's Revenue Growth (%) is ranked higher than
77% of the 626 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. TEVJF: 10.90 )
TEVJF' s 10-Year Revenue Growth (%) Range
Min: 10.2   Max: 23.4
Current: 10.9

10.2
23.4
EBITDA Growth (%) -10.40
TEVJF's EBITDA Growth (%) is ranked higher than
57% of the 592 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.60 vs. TEVJF: -10.40 )
TEVJF' s 10-Year EBITDA Growth (%) Range
Min: -10.4   Max: 47.2
Current: -10.4

-10.4
47.2
EPS Growth (%) -25.60
TEVJF's EPS Growth (%) is ranked higher than
56% of the 593 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.40 vs. TEVJF: -25.60 )
TEVJF' s 10-Year EPS Growth (%) Range
Min: -25.6   Max: 69.8
Current: -25.6

-25.6
69.8
» TEVJF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with TEVJF



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 33.60
TEVJF's P/E(ttm) is ranked higher than
77% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 40.50 vs. TEVJF: 33.60 )
TEVJF' s 10-Year P/E(ttm) Range
Min: 10.53   Max: 1072.29
Current: 33.6

10.53
1072.29
P/B 2.00
TEVJF's P/B is ranked higher than
81% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. TEVJF: 2.00 )
TEVJF' s 10-Year P/B Range
Min: 1.37   Max: 7
Current: 2

1.37
7
P/S 2.16
TEVJF's P/S is ranked higher than
77% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.57 vs. TEVJF: 2.16 )
TEVJF' s 10-Year P/S Range
Min: 1.58   Max: 5.94
Current: 2.16

1.58
5.94
PFCF 58.20
TEVJF's PFCF is ranked higher than
83% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. TEVJF: 58.20 )
TEVJF' s 10-Year PFCF Range
Min: 9.63   Max: 64.03
Current: 58.2

9.63
64.03
EV-to-EBIT 32.75
TEVJF's EV-to-EBIT is ranked higher than
74% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.97 vs. TEVJF: 32.75 )
TEVJF' s 10-Year EV-to-EBIT Range
Min: 11.7   Max: 991
Current: 32.75

11.7
991
PEG 2.00
TEVJF's PEG is ranked higher than
89% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 356.67 vs. TEVJF: 2.00 )
TEVJF' s 10-Year PEG Range
Min: 0.43   Max: 116.41
Current: 2

0.43
116.41
Shiller P/E 22.00
TEVJF's Shiller P/E is ranked higher than
90% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. TEVJF: 22.00 )
TEVJF' s 10-Year Shiller P/E Range
Min: 14.03   Max: 78.77
Current: 22

14.03
78.77
Current Ratio 1.18
TEVJF's Current Ratio is ranked higher than
51% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. TEVJF: 1.18 )
TEVJF' s 10-Year Current Ratio Range
Min: 1.06   Max: 2.95
Current: 1.18

1.06
2.95
Quick Ratio 0.74
TEVJF's Quick Ratio is ranked lower than
52% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.67 vs. TEVJF: 0.74 )
TEVJF' s 10-Year Quick Ratio Range
Min: 0.68   Max: 2.19
Current: 0.74

0.68
2.19

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.30
TEVJF's Dividend Yield is ranked higher than
78% of the 452 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.37 vs. TEVJF: 2.30 )
TEVJF' s 10-Year Dividend Yield Range
Min: 0.18   Max: 2.76
Current: 2.3

0.18
2.76
Dividend Payout 0.68
TEVJF's Dividend Payout is ranked higher than
95% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. TEVJF: 0.68 )
TEVJF' s 10-Year Dividend Payout Range
Min: 0.04   Max: 5
Current: 0.68

0.04
5
Dividend growth (3y) 17.60
TEVJF's Dividend growth (3y) is ranked higher than
89% of the 317 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.50 vs. TEVJF: 17.60 )
TEVJF' s 10-Year Dividend growth (3y) Range
Min: -6.7   Max: 80.9
Current: 17.6

-6.7
80.9
Yield on cost (5-Year) 5.70
TEVJF's Yield on cost (5-Year) is ranked higher than
95% of the 459 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. TEVJF: 5.70 )
TEVJF' s 10-Year Yield on cost (5-Year) Range
Min: 0.45   Max: 6.84
Current: 5.7

0.45
6.84
Share Buyback Rate 2.60
TEVJF's Share Buyback Rate is ranked higher than
90% of the 554 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -1.50 vs. TEVJF: 2.60 )
TEVJF' s 10-Year Share Buyback Rate Range
Min: 2.6   Max: -10.9
Current: 2.6

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 0.90
TEVJF's Price/DCF (Projected) is ranked higher than
97% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. TEVJF: 0.90 )
TEVJF' s 10-Year Price/DCF (Projected) Range
Min: 0.59   Max: 29.17
Current: 0.9

0.59
29.17
Price/Median PS Value 0.60
TEVJF's Price/Median PS Value is ranked higher than
92% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.23 vs. TEVJF: 0.60 )
TEVJF' s 10-Year Price/Median PS Value Range
Min: 0.47   Max: 1.7
Current: 0.6

0.47
1.7
Price/Peter Lynch Fair Value 2.70
TEVJF's Price/Peter Lynch Fair Value is ranked higher than
88% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. TEVJF: 2.70 )
TEVJF' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.57   Max: 98.72
Current: 2.7

0.57
98.72
Earnings Yield (Greenblatt) 3.00
TEVJF's Earnings Yield (Greenblatt) is ranked higher than
62% of the 621 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.00 vs. TEVJF: 3.00 )
TEVJF' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 8.6
Current: 3

0.1
8.6
Forward Rate of Return (Yacktman) 16.24
TEVJF's Forward Rate of Return (Yacktman) is ranked higher than
86% of the 622 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.99 vs. TEVJF: 16.24 )
TEVJF' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 6.6   Max: 37.5
Current: 16.24

6.6
37.5

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:TEVA.USA, TEV.Germany
Teva Pharmaceutical Industries Ltd develops, produces and markets generic, branded & OTC medicines. Some of its products are Copaxone, Azilect & Provigil.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide